Joost Kolkman

VP, Head of Biologics and Co-founder

With over 25 years of experience in antibody discovery and development, he has played a key role in advancing therapeutic candidates in oncology, immunology, and infectious diseases. Prior to Onco3R, Joost served as Director of Antibody Discovery at Galapagos, where he led the company’s biologics strategy and discovery efforts in both oncology and immunology. Previously, Joost held senior roles at Janssen Pharmaceutica (J&J Innovative Medicine) in the Infectious Diseases Therapeutic Area, where he led multiple biologics programs from discovery through early development. Prior to that, he held positions of increasing responsibility at Ablynx, where he was instrumental in the discovery of Nanobody® candidates including vobarilizumab and sonelokimab. Earlier in his career, Joost co-founded Avidia Inc., an antibody mimetics company acquired by Amgen in 2006. He holds a PhD in Pharmaceutical Sciences from Utrecht University in the Netherlands. Joost is recognized for his innovation in biologics platform technologies and his deep expertise in translating antibody discovery into clinical candidates.